Data for: A phase II, multicenter, single-arm trial of eribulin as first-line therapy for aggressive taxane-pretreated HER2-negative metastatic breast cancer patients: The MERIBEL study

Name: Data for: A phase II, multicenter, single-arm trial of eribulin as first-line therapy for aggressive taxane-pretreated HER2-negative metastatic breast cancer patients: The MERIBEL study
Creator: Antonio Llombart
Published: 2019-01-09T15:07:18.323Z
Keywords: Oncologist, Publication

Llombart, Antonio; Antón, Antonio; Garau, Isabel; García, Mirta; Illarramendi, José Juan; Rodriguez, Cesar; Afonso, Noemia; Aguirre, Elena; Zamora, Pilar; Sampayo, Miguel; Ortega, Vanesa; Blanco, Esperanza; Martínez-García, María; Cortes, Javier; Calvo, Lourdes; Perez Garcia, Jose; Fernández, Yolanda

doi:10.17632/ffg8fv5ph5.1

Data for: A phase II, multicenter, single-arm trial of eribulin as first-line therapy for aggressive taxane-pretreated HER2-negative metastatic breast cancer patients: The MERIBEL study

Published: 9 January 2019| Version 1 | DOI: 10.17632/ffg8fv5ph5.1

Contributors:

Antonio Llombart,

Antonio Antón,

Isabel Garau,

Mirta García,

José Juan Illarramendi,

Cesar Rodriguez,

Noemia Afonso,

Elena Aguirre,

Pilar Zamora,

Miguel Sampayo,

Vanesa Ortega,

Esperanza Blanco,

María Martínez-García,

Javier Cortes,

Lourdes Calvo,

Jose Perez Garcia,

Yolanda Fernández

Description

A phase II, multicenter, single-arm trial of eribulin as first-line therapy for aggressive taxane-pretreated HER2-negative metastatic breast cancer patients: The MERIBEL study

Data for: A phase II, multicenter, single-arm trial of eribulin as first-line therapy for aggressive taxane-pretreated HER2-negative metastatic breast cancer patients: The MERIBEL study

Description

Files